Last reviewed · How we verify
Adalimumab, current formulation
Tumor necrosis factor-alpha inhibitor
Tumor necrosis factor-alpha inhibitor Used for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis.
At a glance
| Generic name | Adalimumab, current formulation |
|---|---|
| Also known as | Humira |
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Adalimumab binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and subsequent inflammatory response.
Approved indications
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Crohn's Disease
- Ulcerative Colitis
Common side effects
- Injection site reaction
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Adalimumab in JIA-associated Uveitis Stopping Trial (PHASE4)
- Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis (PHASE2)
- A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety (PHASE2)
- A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab (PHASE2)
- Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adalimumab, current formulation CI brief — competitive landscape report
- Adalimumab, current formulation updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI